SOLID TUMOR CELL THERAPY
We seed a mini-immune system inside the tumor to destroy cancer from within.
Defiant Therapeutics is developing ReCharge, a non-engineered cell therapy designed to seed a miniature immune system inside solid tumors and help the patient’s own immune system coordinate an anti-cancer response within the tumor and beyond.
What we are building
Single-injection therapy
An intratumoral approach designed to form a miniature immune system directly at the cancer site.
Faster manufacturing
A non-engineered autologous cell therapy workflow targeting treatment readiness in days, not weeks.
Platform potential
A platform approach being developed across solid tumor indications where durable immune activation is needed.
How ReCharge works
Solid tumors can suppress immune activity and prevent immune cells from mounting an effective response. ReCharge is designed to create a miniature immune system—technically, a tertiary lymphoid structure—directly inside the tumor, providing a local base of operations for the patient’s own immune system. Using the patient’s own cells without genetic engineering, ReCharge is being developed as a faster, simpler cell therapy platform with potential across solid tumors.
Team
